NGNE · Nasdaq · CIK 0001404644

Neurogene Inc.

Neurogene Inc.’s most recent SEC filing in our snapshot is a Form SCHEDULE 13G filed on Oct 7, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $0 and net income of -$90.4M, according to its XBRL data on EDGAR. Its EDGAR record lists 20 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
$0
Net income, FY2025
-$90.4M
Form 4 filings on record, past 12 months
20

Company overview

Legal name (as filed)
Neurogene Inc.
Ticker
NGNE
SEC Central Index Key (CIK)
0001404644
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
NEW YORK, NY
State or country of incorporation
—
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer<br>Smaller reporting company
Position in SEC ticker list
#2923 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Neurogene Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.

Revenue
n/aFY2021n/aFY2022$0FY2023$925.0KFY2024$0FY2025
Net income
-$60.7MFY2021-$55.2MFY2022-$36.3MFY2023-$75.1MFY2024-$90.4MFY2025
NGNE annual results
ItemFY2021
ended Dec 31, 2021		FY2022
ended Dec 31, 2022		FY2023
ended Dec 31, 2023		FY2024
ended Dec 31, 2024		FY2025
ended Dec 31, 2025
Revenue——$0$925.0K$0
Net income-$60.7M-$55.2M-$36.3M-$75.1M-$90.4M
Diluted EPS-$1.10-$1.04—-$4.28-$4.24
Total assets$163.3M$109.3M$222.6M$335.7M$288.6M
Cash and equivalents$142.5M$82.0M$148.2M$136.6M$103.8M

XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

NGNE latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 24, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 11, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 11, 20268-KResults of operations· period Aug 11, 2026Document · Index
Apr 16, 2026DEF 14ADefinitive proxy statement· period Jun 3, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Neurogene Inc., by form type:

4 ×118-K ×8SCHEDULE 13G ×34/A ×3144 ×2SCHEDULE 13G/A ×210-Q ×2424B5 ×23 ×13/A ×1DEFA14A ×1DEF 14A ×1ARS ×1S-8 ×110-K ×1
NGNE recent filings
FiledFormWhat it isOriginal
Oct 7, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Oct 6, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Oct 2, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 22, 2026Document · Index
Aug 14, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 14, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
Aug 14, 2026SCHEDULE 13G/APassive beneficial ownership report (over 5%)Document · Index
Aug 11, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 11, 20268-KResults of operations· period Aug 11, 2026Document · Index
Jul 7, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 6, 2026Document · Index
Jul 2, 2026424B5424B5Document · Index
Jul 2, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 1, 2026Document · Index
Jul 2, 20268-KMaterial agreement; Other events· period Jun 30, 2026Document · Index
Jun 30, 2026424B5424B5Document · Index
Jun 29, 20268-KRegulation FD disclosure; Other events· period Jun 29, 2026Document · Index
Jun 16, 20264/AStatement of changes in beneficial ownership (insider trade)· period Jan 16, 2024Document · Index
Jun 16, 20264/AStatement of changes in beneficial ownership (insider trade)· period Jun 14, 2024Document · Index
Jun 16, 20264/AStatement of changes in beneficial ownership (insider trade)· period Jun 12, 2025Document · Index
Jun 16, 20263/AInitial statement of beneficial ownership· period Dec 18, 2023Document · Index
Jun 8, 20268-KRegulation FD disclosure· period Jun 8, 2026Document · Index
Jun 4, 20268-KShareholder vote results· period Jun 3, 2026Document · Index
May 12, 20268-KResults of operations· period May 12, 2026Document · Index
May 12, 202610-QQuarterly report· period Mar 31, 2026Document · Index
May 8, 20264Statement of changes in beneficial ownership (insider trade)· period May 6, 2026Document · Index
May 7, 20264Statement of changes in beneficial ownership (insider trade)· period May 5, 2026Document · Index
May 6, 2026144Notice of proposed sale of securitiesDocument · Index
Apr 20, 20263Initial statement of beneficial ownership· period Apr 20, 2026Document · Index
Apr 20, 20268-KDirector or officer change; Regulation FD disclosure· period Apr 20, 2026Document · Index
Apr 16, 2026DEFA14AAdditional proxy soliciting materialsDocument · Index
Apr 16, 2026DEF 14ADefinitive proxy statement· period Jun 3, 2026Document · Index
Apr 16, 2026ARSARS· period Dec 31, 2025Document · Index
Mar 30, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 26, 2026Document · Index
Mar 30, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 26, 2026Document · Index
Mar 30, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 26, 2026Document · Index
Mar 24, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Mar 24, 202610-KAnnual report· period Dec 31, 2025Document · Index
Mar 24, 20268-KResults of operations· period Mar 24, 2026Document · Index
Mar 17, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 13, 2026Document · Index
Mar 17, 20264Statement of changes in beneficial ownership (insider trade)· period Mar 13, 2026Document · Index
Mar 13, 2026144Notice of proposed sale of securitiesDocument · Index
Mar 3, 20264Statement of changes in beneficial ownership (insider trade)· period Feb 27, 2026Document · Index

Insider filing activity

20 Form 4 filings appear in Neurogene Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in New York

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001404644 and XBRL company facts. Neurogene Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.